Citation Impact
Citing Papers
MRS in presymptomatic MAPT mutation carriers
2010
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
2012 StandoutScience
Deep Brain Stimulation for Treatment-Resistant Depression
2005 Standout
Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease
2015
Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations
1999
Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
2017
Parkinson's disease
2021 Standout
Parkinson's Disease
1998
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
2008 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
2017
Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression
1999
Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons
2007
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
2012 Standout
Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene
1992 StandoutNobel
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
2004
The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease
2000
Delirium in elderly people
2013 Standout
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
2015 Standout
Atomic structures of amyloid cross-β spines reveal varied steric zippers
2007 StandoutNature
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered
2006
Staging of brain pathology related to sporadic Parkinson’s disease
2002 Standout
Stages in the development of Parkinson’s disease-related pathology
2004 Standout
Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies
1998
Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs
1997
Cognitive status correlates with neuropathologic stage in Parkinson disease
2005
A systematic review of prevalence studies of depression in Parkinson's disease
2007 Standout
Epidemiology of Parkinson's disease
2006 Standout
The genetics and neuropathology of Parkinson’s disease
2012
CSF markers for incipient Alzheimer's disease
2003
Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
2003
Parkinson's disease
2009 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Protein aggregation and neurodegenerative disease
2004 Standout
Parkinson's disease
2015 Standout
The Future of Memory: Remembering, Imagining, and the Brain
2012 StandoutNobel
Oxidative stress in Parkinson's disease
2003 Standout
Mutant prion proteins in Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles
1992 StandoutNobel
PINK1-linked parkinsonism is associated with Lewy body pathology
2010
Colocalization of prion protein and ? protein in the same amyloid plaques in patients with Gerstmann-Str�ussler Syndrome
1992
Parkinson's disease: a dual‐hit hypothesis
2007
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
Human prion diseases
1994 StandoutNobel
Alzheimer's disease
2006 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
Dopaminergic modulation of cortico-cortical functional connectivity in Parkinson's disease: An MEG study
2008
The Amyloid State of Proteins in Human Diseases
2012 Standout
A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)
1999
Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease
2005
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen
2003
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
2003 Standout
Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities
2012 StandoutNobel
Non-invasive imaging of neuropathology in a rat model of α-synuclein overexpression
2006
A systematic review of prevalence studies of dementia in Parkinson's disease
2005 Standout
Alzheimer's Disease
2004 Standout
Insoluble wild–type and protease–resistant mutant prion protein in brains of patients with inherited prion disease
1996 StandoutNobel
Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors
2009 Standout
Dementia associated with Parkinson's disease
2003
Future thinking in Parkinson's disease: An executive function?
2012
The molecular pathology of Alzheimer's disease
1991 Standout
Complex brain networks: graph theoretical analysis of structural and functional systems
2009 Standout
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
2005 Standout
Mental symptoms in Parkinson's disease are important contributors to caregiver distress
1999
Prevalence and Treatment of Depression in Parkinson’s Disease
2005
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
2002 StandoutScience
Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation
1997 StandoutNobel
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Prion Diseases and Neurodegeneration
1994 StandoutNobel
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)
2006 Standout
Hydrogel bioelectronics
2018 Standout
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 Standout
Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid.
1992 StandoutNobel
Physical Activity and Public Health in Older Adults
2007 Standout
Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes
2003 StandoutScience
Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein.
1994 StandoutNobel
Biological Markers in Alzheimer Disease
2002
MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins
1997
Recognition and Treatment of Depression in Parkinson's Disease
2003
Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging.
2000
Fibrillar β-Amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat CNSIn Vivo
1998
Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred.
1992 StandoutNobel
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
2008 Standout
Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
1999
Works of E.Ch. Wolters being referenced
Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy
1994
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
1996
Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia
2007
Evaluation of [123I]β-CIT binding with SPECT in controls, early and late Parkinson's disease
1995
Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease
1995
rCBF SPECT in Parkinson’s disease patients with mental dysfunction
1997
[ 123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease
2001
Rapidly progressive autosomal dominant parkinsonism and dementia with pallido‐ponto‐nigral degeneration
1992
Depression in Parkinson’s Disease: The Impact of Symptom Overlap on Prevalence
1998
Sleep apnea syndrome presenting with cognitive impairment
1991
Preclinical (premotor) Parkinson’s disease
2000
Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis
1990
DGAVP (Org 5667) in early Alzheimer??s disease patients: an international double-blind, placebo-controlled multicenter trial
1991
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
1998
Cognitive dysfunction and dementia in Parkinson?s disease
2004